We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LMT:NYSELockheed Martin Corporation Analysis

Data as of 2026-04-15 - not real-time

$611.58

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Lockheed Martin is trading at $611.58, which sits below its 20‑day SMA of 622 and well under the 50‑day SMA of 637, signaling short‑term weakness. The 14‑day RSI of 43.5 places the stock in a neutral zone, offering no clear overbought or oversold signal. A bearish MACD histogram of –0.63 reinforces the downside bias on the technical front. Current price is perched just above the calculated support level of $593.88, while resistance sits near $645.85. Volume trends are decreasing, which can limit upside momentum in the near term. Despite a low beta of roughly 0.15 and a 30‑day volatility of 23%, the market is pricing the shares at a significant premium to the DCF fair value of $375.
On the fundamental side, LMT posted 9.1% revenue growth and an extraordinary ROE of 77%, reflecting the profitability of its defense contracts. The company generates robust operating cash flow of $8.6 bn and free cash flow of $5.3 bn, comfortably covering its 2.21% dividend with a 62% payout ratio. Recent material news highlights a new $4.7 bn Army contract and inclusion in top drone‑stock lists, underscoring a strong order pipeline. However, the balance sheet carries a high debt‑to‑equity ratio of 339%, which could constrain financial flexibility. The defense sector’s reliance on government spending introduces medium regulatory and sector risk, though geographic concentration in the U.S. keeps currency exposure low. Given the blend of solid fundamentals, dividend appeal, and overvalued market pricing, a cautious “hold” stance is prudent across investment horizons.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • price below 20‑day and 50‑day SMAs
  • bearish MACD signal
  • decreasing volume

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • strong cash flow and dividend yield
  • new multi‑billion defense contracts
  • high debt‑to‑equity ratio limiting upside

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • secular defense spending
  • high ROE and profitability
  • low beta and defensive sector positioning

Key Metrics & Analysis

Financial Health

Revenue Growth9.10%
Profit Margin6.69%
P/E Ratio28.4
ROE76.87%
ROA7.57%
Debt/Equity338.80
P/B Ratio20.8
Op. Cash Flow$8.6B
Free Cash Flow$5.3B
Industry P/E31.2

Technical Analysis

TrendNeutral
RSI43.5
Support$593.88
Resistance$645.85
MA 20$622.18
MA 50$637.42
MA 200$518.84
MACDBearish
VolumeDecreasing
Fear & Greed Index88.64

Valuation

Fair Value$375.34
Target Price$667.85
Upside/Downside9.20%
GradeOvervalued
TypeBlend
Dividend Yield2.21%

Risk Assessment

Beta0.15
Volatility23.08%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.